CD44 as a tumor biomarker and therapeutic target.
Xu H, Niu M, Yuan X, Wu K, Liu A. · 2020
Read CD44 as a tumor biomarker and therapeutic target. by Xu H, Niu M, Yuan X, Wu K, Liu A. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7727191.txt.
Description
Xu and co-authors review CD44, a surface protein tied to tumor growth and spread. CD44 comes in a standard form and many variant forms. It marks cancer stem cells in many tumors. It also drives the shape shift that lets cancer cells move and invade.
CD44 feeds into many signal paths that steer growth, spread, and drug resistance. High levels often mean a poor outlook for patients. Trials have tested antibodies against CD44 for safety and effect. The authors set out its structure, its controls, and its roles step by step. They frame CD44 as a drug target worth the effort to hit well.
Catalog record
| CREATOR | Xu H, Niu M, Yuan X, Wu K, Liu A. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |